www.fdanews.com/articles/101354-gni-announces-ind-approval-in-china-for-novel-liver-disease-drug-f351
GNI Announces IND Approval in China for Novel Liver Disease Drug F351
November 21, 2007
GNI Ltd., a leading biopharmaceutical company in Japan and China, is pleased to announce that the State Food and Drug Administration of China has approved its investigational new drug application (IND) for the clinical development of one of its lead drug candidates, F351, for the treatment of liver fibrosis/cirrhosis.
Business Wire